Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Allegra, Children's Allegra Allergy, Children's Allegra Hives, Allegra Allergy, Allegra Hives. Every FDA application for this active ingredient: 5 branded and 22 generic.
As of Nov 22, 2026, FDA lists 27 applications for Fexofenadine hydrochloride (sold as Allegra, Children's Allegra Allergy, Children's Allegra Hives and others), first approved Jul 25, 1996, with 7 new uses approved and 0 published complete response letters.
Each condition ChEMBL records for this drug, with the furthest stage reached and the trials it cites; approved means approved for that use somewhere, not necessarily in the US
Cases reported to FDA naming this drug as the primary suspect, 2025 Q4 to 2026 Q3, from FDA's quarterly files. A report does not show the drug caused the event.
No adverse event (372), Drug ineffective (250), Off label use (53), Rash (36), Pruritus (36), Therapeutic product effect incomplete (32), Urticaria (29), Palpitations (29), Insomnia (28), Drug effect less than expected (27)
FDA drug safety communications
One communication since 2020 that name this drug; see all communications
Allegra, new approvalA drug with a new additional pediatric (6 months of age and older and less than 7 years of age) dosage in an additional dosage form of dry syrup. · Sanofi K.K. · Jan 17, 2014
Approvals in Canada (Health Canada)
First approved in Canada 11 months after the US. New drug submissions since 1994, matched by ingredient; see all Canadian approvals
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered.Drugs@FDA